Nykredit A S Invests Heavily in Amgen Inc. Amid Ongoing Patent Risks

Nykredit A S has invested in Amgen Inc., purchasing 135,233 shares of the medical research company's stock for approximately $48.971 million in the second quarter, according to its Form 13F filing with the Securities & Exchange Commission.

This is not the only institutional investor that has added to or reduced their stakes in Amgen recently. BlackRock Inc. grew its stake by 4.8% in the same period, while State Street Corp and Capital World Investors also increased their holdings in the company.

Amgen's stock opened at $385.65 on Friday and has a one-year high of $447.03 and a one-year low of $269.77. The company has a market capitalization of $208.49 billion, a P/E ratio of 23.97, and a beta of 0.43.